Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026

Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026
Upstream Bio unveils new trial data

Upstream Bio, Inc. has unveiled additional analyses from the VIBRANT Phase 2 trial of verekitug targeting chronic rhinosinusitis with nasal polyps at the AAAAI2026 conference.

The presentation highlights ongoing research efforts aimed at addressing treatment gaps in chronic rhinosinusitis with nasal polyps, a condition that significantly impacts patient quality of life. The latest findings build on previously reported data, offering new insights into the efficacy and safety profile of verekitug in this patient population.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.